https://www.selleckchem.com/pr....oducts/bay-11-7082-b
001); no large differences were observed among allergens. Among the subjects who failed LD-OFCs, the median change in the total dose in the LD-OFC was 235% (interquartile range 100%-512%) in the SLOIT group and 100% (42%-235%) in the control group (P less then .001). Provoked allergic symptoms were observed in only 0.58% (280/48,486) per programmed intake and approximately 50% of the SLOIT group did not experience any obvious allergic symptoms throughout therapy. Conclusions SLOIT showed significant feasibility, efficacy
Like
Comment
Share
